Human papillomavirus vaccines have been in use in populations for nearly 10 years. They
now have an established record of high efficacy, effectiveness and safety in the prevention …

The casual relationship concerning Human papillomaviruses (HPV) and cervical cancer is
already established. Therefore, such HPV-associated malignancies might be prevented by …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …

Human papilloma virus (HPV) vaccination has been implemented in several countries for
about the past 7 years, mainly in the adolescent female population, with varying coverage …

For more than a decade human papillomavirus (HPV) vaccine have been implemented in
most high-income countries, and more recently also in several low-and middle-income …

The link between human papillomavirus (HPV) infection and different diseases has been
well-established since more than four decades ago [1, 2]. Moreover, high-risk HPV types …

Two licensed vaccines designed to prevent certain human papillomavirus (HPV) infections
are currently available. Their use to prevent cervical cancer has depended on data from …

The risk for acquiring human papillomavirus (HPV) infections and associated diseases is
lifelong. An important part of prophylactic HPV vaccine development is durable protection …

Studies with prophylactic HPV vaccination have demonstrated impressive efficacy,
immunogenicity, and safety results; however, the implementation and uptake in both low and …

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …